- Home
- TULP vs PASG Comparison
TULP vs PASG Comparison
Compare TULP & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TULP | PASG |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.8M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TULP | PASG |
|---|---|---|
| Price | $3.46 | $4.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 3.4K | ★ 15.1K |
| Earning Date | 02-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.11 | $3.29 |
| 52 Week High | $4.79 | $20.00 |
Technical Indicators
Market Signals| Indicator | TULP | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 40.50 |
| Support Level | $3.11 | $4.25 |
| Resistance Level | $3.96 | $4.94 |
| Average True Range (ATR) | 0.15 | 0.27 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 52.11 | 20.83 |
Price Performance
Historical ComparisonAbout TULP Bloomia Holdings Inc. Common Stock
Bloomia Holdings Inc is a specialty ag company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.